The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -24.15 — distress zone — historically elevated failure riskWatch
Leadership changes
From Aligos Therapeutics, Inc.'s own filings, the day they're filed.
- Nikhil Aneja · Principal Accounting Officer · appointmenteff. 2026-01-29
- Lesley Ann Calhoun · Chief Operating Officer · appointmenteff. 2025-01-30
- Matthew McClure · Chief Medical Officer · departureeff. 2024-05-09
Latest filings
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- DEF 14A · Annual proxy (pay & governance)2026-04-29
- 8-K · Company announcement2026-04-21
- 8-K · Company announcement2026-04-14
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Aligos Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Aligos Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.